

A Novel Antibody-drug Conjugate Targeting Stage-specific Embryonic Antigen 4

Drug Name	***0130
Description	A novel antibody-drug conjugate (ADC) targeting stage-specific embryonic antigen 4 (SSEA-4) is being investigated in preclinical studies for cancer therapy. Compared to conventional chemotherapeutic drugs, the ADC targets tumors expressing SSEA-4 and releases cytotoxic payload to directly shrink or eradicate tumors.
Target	SSEA-4
Drug Modality	Antibody-Drug Conjugate
Indication	Cancer
Product Category	Cancer Immunotherapy
Mechanism of Action	Targeting SSEA-4
Status	Preclinical
Patent	Granted

More Detail Available Upon Request

We look forward to hearing from you.